Matches in SemOpenAlex for { <https://semopenalex.org/work/W4289936629> ?p ?o ?g. }
- W4289936629 endingPage "2307" @default.
- W4289936629 startingPage "2280" @default.
- W4289936629 abstract "Biomarkers guiding the neoadjuvant use of immune-checkpoint blockers (ICB) are needed for patients with localized muscle-invasive bladder cancers (MIBC). Profiling tumor and blood samples, we found that follicular helper CD4+ T cells (TFH) are among the best therapeutic targets of pembrolizumab correlating with progression-free survival. TFH were associated with tumoral CD8 and PD-L1 expression at baseline and the induction of tertiary lymphoid structures after pembrolizumab. Blood central memory TFH accumulated in tumors where they produce CXCL13, a chemokine found in the plasma of responders only. IgG4+CD38+ TFH residing in bladder tissues correlated with clinical benefit. Finally, TFH and IgG directed against urothelium-invasive Escherichia coli dictated clinical responses to pembrolizumab in three independent cohorts. The links between tumor infection and success of ICB immunomodulation should be prospectively assessed at a larger scale.In patients with bladder cancer treated with neoadjuvant pembrolizumab, E. coli-specific CXCL13 producing TFH and IgG constitute biomarkers that predict clinical benefit. Beyond its role as a biomarker, such immune responses against E. coli might be harnessed for future therapeutic strategies. This article is highlighted in the In This Issue feature, p. 2221." @default.
- W4289936629 created "2022-08-06" @default.
- W4289936629 creator A5000473619 @default.
- W4289936629 creator A5001000565 @default.
- W4289936629 creator A5004620741 @default.
- W4289936629 creator A5005981381 @default.
- W4289936629 creator A5007309998 @default.
- W4289936629 creator A5009617794 @default.
- W4289936629 creator A5013766193 @default.
- W4289936629 creator A5015036334 @default.
- W4289936629 creator A5016175389 @default.
- W4289936629 creator A5018277488 @default.
- W4289936629 creator A5020529503 @default.
- W4289936629 creator A5021067733 @default.
- W4289936629 creator A5021545250 @default.
- W4289936629 creator A5023794502 @default.
- W4289936629 creator A5027991868 @default.
- W4289936629 creator A5028695173 @default.
- W4289936629 creator A5031056221 @default.
- W4289936629 creator A5031903089 @default.
- W4289936629 creator A5032887239 @default.
- W4289936629 creator A5033054923 @default.
- W4289936629 creator A5035950152 @default.
- W4289936629 creator A5037504237 @default.
- W4289936629 creator A5039277233 @default.
- W4289936629 creator A5039469080 @default.
- W4289936629 creator A5041156154 @default.
- W4289936629 creator A5042535284 @default.
- W4289936629 creator A5042575799 @default.
- W4289936629 creator A5045293467 @default.
- W4289936629 creator A5046736174 @default.
- W4289936629 creator A5046867675 @default.
- W4289936629 creator A5051834284 @default.
- W4289936629 creator A5054491406 @default.
- W4289936629 creator A5056596174 @default.
- W4289936629 creator A5056844302 @default.
- W4289936629 creator A5060675099 @default.
- W4289936629 creator A5062713851 @default.
- W4289936629 creator A5063056885 @default.
- W4289936629 creator A5063565156 @default.
- W4289936629 creator A5064138384 @default.
- W4289936629 creator A5064914239 @default.
- W4289936629 creator A5065206480 @default.
- W4289936629 creator A5067036952 @default.
- W4289936629 creator A5069250904 @default.
- W4289936629 creator A5069333253 @default.
- W4289936629 creator A5070068983 @default.
- W4289936629 creator A5070354041 @default.
- W4289936629 creator A5071036901 @default.
- W4289936629 creator A5071855898 @default.
- W4289936629 creator A5074336646 @default.
- W4289936629 creator A5074612242 @default.
- W4289936629 creator A5075296559 @default.
- W4289936629 creator A5078061987 @default.
- W4289936629 creator A5085212825 @default.
- W4289936629 creator A5085320680 @default.
- W4289936629 creator A5087389602 @default.
- W4289936629 creator A5087562469 @default.
- W4289936629 creator A5087712188 @default.
- W4289936629 creator A5090177578 @default.
- W4289936629 creator A5090249273 @default.
- W4289936629 creator A5090400353 @default.
- W4289936629 creator A5090538658 @default.
- W4289936629 date "2022-08-05" @default.
- W4289936629 modified "2023-10-17" @default.
- W4289936629 title "<i>Escherichia coli</i>–Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer" @default.
- W4289936629 cites W1538902372 @default.
- W4289936629 cites W1631320694 @default.
- W4289936629 cites W1966960698 @default.
- W4289936629 cites W1970663322 @default.
- W4289936629 cites W1987979188 @default.
- W4289936629 cites W1990943122 @default.
- W4289936629 cites W2009720434 @default.
- W4289936629 cites W2019875425 @default.
- W4289936629 cites W2031240692 @default.
- W4289936629 cites W2037713737 @default.
- W4289936629 cites W2039123767 @default.
- W4289936629 cites W2066671159 @default.
- W4289936629 cites W2107484016 @default.
- W4289936629 cites W2118982164 @default.
- W4289936629 cites W2124427232 @default.
- W4289936629 cites W2150048477 @default.
- W4289936629 cites W2165456770 @default.
- W4289936629 cites W2172112723 @default.
- W4289936629 cites W2185075416 @default.
- W4289936629 cites W2257999935 @default.
- W4289936629 cites W2281666530 @default.
- W4289936629 cites W2462649057 @default.
- W4289936629 cites W2470127204 @default.
- W4289936629 cites W2503748529 @default.
- W4289936629 cites W2528306813 @default.
- W4289936629 cites W2528849844 @default.
- W4289936629 cites W2529169580 @default.
- W4289936629 cites W2559804019 @default.
- W4289936629 cites W2571861015 @default.
- W4289936629 cites W2582671354 @default.
- W4289936629 cites W2588916311 @default.
- W4289936629 cites W2605630275 @default.